Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $237.91, for a total value of $856,476.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at $30,928.30. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

United Therapeutics Stock Up 0.4 %

Shares of United Therapeutics stock traded up $1.00 on Friday, reaching $237.93. The company’s stock had a trading volume of 616,033 shares, compared to its average volume of 434,215. The company has a market capitalization of $11.20 billion, a price-to-earnings ratio of 11.99 and a beta of 0.52. The firm’s fifty day simple moving average is $231.20 and its two-hundred day simple moving average is $228.44. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $261.54. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. The business had revenue of $614.70 million during the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company’s quarterly revenue was up 25.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.67 EPS. Equities analysts anticipate that United Therapeutics Co. will post 23.46 earnings per share for the current year.

Institutional Trading of United Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of UTHR. Rise Advisors LLC bought a new stake in shares of United Therapeutics in the first quarter worth $32,000. GAMMA Investing LLC bought a new stake in shares of United Therapeutics in the fourth quarter worth $43,000. Neo Ivy Capital Management bought a new stake in shares of United Therapeutics in the second quarter worth $48,000. Atlas Capital Advisors LLC bought a new stake in shares of United Therapeutics in the fourth quarter worth $51,000. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in shares of United Therapeutics by 49.6% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 65 shares during the period. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the topic of several recent research reports. Wedbush restated an “outperform” rating and set a $308.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and lifted their price objective for the stock from $213.00 to $215.00 in a research report on Monday, February 12th. SVB Leerink assumed coverage on United Therapeutics in a research report on Monday, February 5th. They issued an “outperform” rating and a $330.00 price objective on the stock. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $292.67.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.